Instruction 1(b)

FORM 5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
ao g ,		_00.0	

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL **OWNERSHIP**

OMB APPRO	DVAL					
OMB Number:	3235-0362					
Estimated average burden						
hours per response:	1.0					

Form 3										ho	urs per	response:	1.0			
Form 4	Transactions F	eported.	File	ed pursuant to or Sectior												
1. Name and Address of Reporting Person* FAHIM RAAFAT E F				2. Issuer Name and Ticker or Trading Symbol NABI BIOPHARMACEUTICALS NABI							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O NABI BIOPHARMACEUTICALS 5800 PARK OF COMMERCE BLVD., N.W.					3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2005						/Year)	X Officer (give title Other (specify below) Sr. VP Tech. & Prod.				
(Street) BOCA R (City)	ATON FL		Zip)	4. If Amen	dment	t, Date o	of Orig	ginal File	d (Month/I	Day/Yea	′ I	For	m filed by	One Re	ing (Check eporting Pe nan One Re	rson
		Tabl	e I - Non-Deriv	ative Sec	uritie	es Ac	quire	ed, Di	sposed	of, or	Benefici	ally Own	ed			
Date			2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		4. Securities Acquired (A) or Dispose (D) (Instr. 3, 4 and 5)			or Disposed	Securit Benefic	ies		ership n: Direct	7. Nature of ndirect Beneficial Ownership	
							Amount		(A) or (D)	Price	Issuer's	Issuer's Fiscal Year (Instr. 3 and			(Instr. 4)	
Common Stock 11/30		11/30/2005			J (1)		594.3074		A	\$2.635	5 12,453.42		4267 D			
		Та	ble II - Derivat (e.g., p	tive Secur uts, calls,									i			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	of Deriv	r osed			Amount of Securities Underlying Derivative Security (Instr. and 4) Expiration Amount of Securities Underlying Derivative Security (Instr. and 4)		unt of irities erlying vative irity (Instr. 3	8. Price of Derivative Security (Instr. 5)	derivativ Securitie Beneficie Owned Followin Reported	Securities Beneficially Dwned Following		11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Voluntarily reported acquisition under the issuer's 2000 Employee Stock Purchase Plan, which is an exempt transaction pursuant to Rule 16b-3(c).

Remarks:

/s/ James E. Dawson, as attorney-in-fact

02/14/2006

Date

** Signature of Reporting Person Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.